Combigan Patent Expiration

Combigan is a drug owned by Abbvie Inc. It is protected by 11 US drug patents filed from 2013 to 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 19, 2023. Details of Combigan's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320976 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US9907801 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US9907802 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US7642258 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US8133890 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US8354409 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US8748425 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US9770453 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US9474751 Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US7030149 Combination of brimonidine timolol for topical ophthalmic use
Apr, 2022

(2 years ago)

Expired
US7323463 Combination of brimonidine and timolol for topical ophthalmic use
Jan, 2023

(1 year, 5 months ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Combigan and ongoing litigations to help you estimate the early arrival of Combigan generic.

Combigan's Litigations

Combigan has been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 09, 2015, against patent number US7030149. The petitioner Ferrum Ferro Capital, LLC, challenged the validity or infringement of this patent, with Allergan Sales, LLC as the respondent. Click below to track the latest information on how companies are challenging Combigan's patents.


Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7030149 March, 2015 Terminated-Denied Allergan Sales, LLC Ferrum Ferro Capital, LLC

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Combigan's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Combigan's generic, the next section provides detailed information on ongoing and past EP oppositions related to Combigan patents.

Combigan's oppositions filed in EPO

Combigan has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 04, 2013, by Stada Arzneimittel Ag. This opposition was filed on patent number EP03726234A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP03726234A Oct, 2013 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Revoked
EP03726234A Oct, 2013 Hexal AG Revoked
EP03726234A Oct, 2013 Generics [UK] Limited Revoked
EP03726234A Oct, 2013 Alfred E. Tiefenbacher GmbH & Co. KG Revoked
EP03726234A Oct, 2013 Teva Pharmaceutical Industries LTD. Revoked
EP03726234A Oct, 2013 STADA Arzneimittel AG Revoked


US patents provide insights into the exclusivity only within the United States, but Combigan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combigan's family patents as well as insights into ongoing legal events on those patents.

Combigan's family patents

Combigan has patent protection in a total of 19 countries. It's US patent count contributes only to 46.7% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Combigan.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Combigan's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 19, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Combigan Generics:

Brimonidine Tartrate; Timolol Maleate is the generic name for the brand Combigan. 7 different companies have already filed for the generic of Combigan, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combigan's generic

How can I launch a generic of Combigan before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Combigan's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Combigan's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Combigan -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.2%/0.5% 21 Nov, 2008 1 19 Apr, 2022 Extinguished




About Combigan

Combigan is a drug owned by Abbvie Inc. It is used for lowering elevated intraocular pressure in patients with glaucoma or ocular hypertension. Combigan uses Brimonidine Tartrate; Timolol Maleate as an active ingredient. Combigan was launched by Abbvie in 2007.

Market Authorisation Date:

Combigan was approved by FDA for market use on 30 October, 2007.

Active Ingredient:

Combigan uses Brimonidine Tartrate; Timolol Maleate as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate; Timolol Maleate ingredient

Treatment:

Combigan is used for lowering elevated intraocular pressure in patients with glaucoma or ocular hypertension.

Dosage:

Combigan is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.2%;EQ 0.5% BASE SOLUTION/DROPS Prescription OPHTHALMIC